CAMBRIDGE, MA and SOMERSET, NJ – Apr 27, 2021 — AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a partnership to support the development and manufacturing of AavantiBio’s gene therapies, including its lead program in Friedreich’s Ataxia (FA).
Catalent will provide process development and CGMP manufacturing of AavantiBio’s…
Cambridge, UK: 27th April 2021
One Nucleus, the not-for-profit Life Science membership group headquartered in Cambridge, has welcomed EY to its Partner Programme.
The group supports growing Life Science businesses through their life cycle, as they translate great science into better patient outcomes. This includes facilitating connections between compliance, tax, investment and international growth.
Tony Jones, CEO of One Nucleus commented: ‘We are delighted to welcome EY to the One Nucleus Partner Programme. We look forward to connecting our members with their expertise and platforms such as…
The United Kingdom has become a fully independent third country to the European Union. In this 32 page special report patent specialists Garreth Duncan and Jennifer O’Farrell shine a spotlight on the impact of Brexit on the pharmaceutical industry, focusing on the challenges ahead as well as areas of opportunity for the UK.
Implementing the trade agreement the UK has made with the EU, and working through the inevitable snags, is the next challenge facing the pharmaceutical industry. Coupled with the additional pressures of the Covid-19 pandemic, this represents a significant challenge, but…
Work is set to begin on the first phase of Birmingham Health Innovation Campus this Summer after planning permission was granted by Birmingham City Council.
The first phase will see the development of No.1 Birmingham Health Innovation Campus which will offer 133,000 sq ft of lab and office space purposely designed for health innovation and life sciences businesses, with a focus on those working in medtech, precision medicine, biopharma and digital healthcare.
The building will include the home of the University of Birmingham’s Precision Health Technologies Accelerator…
AMSBIO has launched a comprehensive range of cytosections that offer a verified, reproducible and renewable source of positive / negative controls where the expression of the target biomarker is confirmed for accuracy and specificity by an immunoassay.Researchers, antibody and assay developers as well as Immunohistochemistry (IHC) labs often find it difficult to find a reliable and verified source of positive / negative controls for their IHC experiments. This is especially important when they are developing new IHC protocols for novel targets whose expression pattern is not known…
BERLIN, Germany, April 14, 2021 – LINK Medical, the Northern European clinical research organization (CRO), is continuing the expansion of its German presence. This further strengthens their position as a gateway between the Nordics and one of the largest medical device and pharmaceutical markets in Europe. By establishing a stronger position in Germany, LINK Medical’s global clients get access to Germany’s well-recognized regulatory authorities, its vast network of clinical trial sites and investigators, and Europe’s largest patient population – all key elements for performing high-quality…
30/03/2021 Cambridge UK – SomaServe Ltd, a pioneer in nanomedicines for crossing biological barriers today announced that it has completed a highly successful, oversubscribed Series A funding of £2.1m. SomaServe has also secured further IP and global commercial rights to PolyNaut platform technology (the bionic nanoparticle) from UCLB. The company now has exclusive PolyNaut rights in all indications.
The funding round was jointly led by Meltwind and Origin Capital and had follow on investment from all existing investors including Abcam and o2H Ventures. The success of this funding round is…
Cambridge, United Kingdom and Singapore – 13 April 2021- Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces a strategic partnership with Camtech Diagnostics (“Camtech”), a technology company providing total solutions to the biodefence, food and clinical diagnostics sectors. The partnership covers the distribution of Congenica’s platform in Asia-Pacific.
Under the partnership agreement Camtech will be responsible for the marketing, distribution and sales of Congenica’s clinical decision support…
NORWICH, UK – 13 April 2021: HotHouse BioEngineering (HHBE), which was founded on a body of work from the laboratory of Professor Anne Osbourn FRS OBE of the John Innes Centre, and Leaf Expression Systems (Leaf), a contract development and manufacturing organisation specialising in plant-based expression and production of proteins, today announced a non-exclusive agreement granting HHBE use of Leaf’s expression technology, Hypertrans® for research and development.
HHBE has the ability to rapidly identify and isolate entire biosynthetic pathways from members of the plant kingdom and…
Research Triangle Park, NC, USA and Cambridge, UK, 10 April 2021 -- Inivata, a leader in liquid biopsy, today unveils new data at the American Association for Cancer Research (AACR) Virtual Annual Meeting in support of the capabilities and application of the Company’s liquid biopsy technologies, particularly the RaDaR® assay for the detection of molecular residual disease (MRD) and recurrence.
In two studies, RaDaR demonstrated excellent specificity (100%) and sensitivity (100%) in detecting MRD in patient cohorts with head and neck cancer and early-stage breast cancer. The data are available…